Subscribe To
UBX / Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate
UBX News
By Zacks Investment Research
March 28, 2023
Unity (UNX) Down on Disappointing Results From Wet AMD Study
Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD s more_horizontal
By InvestorPlace
March 27, 2023
Why Is Unity Biotechnology (UBX) Stock Down 52% Today?
Unity Biotechnology (NASDAQ: UBX ) stock is taking a beating on Monday after revealing results from its Phase 2 clinical trial of UBX1325. UBX1325 is more_horizontal
By Benzinga
October 5, 2021
Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate
Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and w more_horizontal
By Benzinga
October 5, 2021
Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate
Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and w more_horizontal
By Benzinga
October 5, 2021
Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate
Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and w more_horizontal
By Benzinga
October 5, 2021
Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate
Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and w more_horizontal
By Benzinga
October 5, 2021
Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate
Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and w more_horizontal